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Background: Detection of neuroendocrine tumor (NET) disease progression is a key issue in determining
management. Currently, assessment is by imaging (MRI/CT and Octreoscan®) and plasma Chromogranin A (CgA)
measurement.
Case presentation: We report use of a NET-specific multigene PCR-derived blood transcript signature (NET Index)
to assess disease and correlated CgA and gene transcripts with MRI, CT, Octreoscan®, 11C-5HTP-PET/CT and
68Ga-DOTA-PET/CT in a patient with NET.
Conclusions: Our results identify limitations in evaluating disease status by CgA and identify that a PCR-based test
is more sensitive. Alteration in NET blood gene transcript levels prior to image-based tumor confirmation suggests
this parameter may also have utility as an index of therapeutic efficacy.
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NET disease is increasing in incidence and prevalence as
attested to by national and internationally derived epi-
demiological data [1]. As a consequence of the increas-
ing awareness of the disease and the introduction of
novel efficacious therapeutic strategies (Everolimus,
Sunitinib, Peptide Radio Receptor Therapy, surgical and
radiofrequency ablative hepatic metastatic techniques),
the clinical relevance of accurately determining the sta-
tus of disease has become an issue of paramount import-
ance. Although early diagnosis of NET disease remains a
key challenge, a further critical emerging management
issue is the limited ability to accurately gauge disease
progress by imaging or biomarker assessment [2].
Failure to identify disease progress early and adjust
therapy and the inability to delineate a lack of thera-
peutic efficacy and expeditiously introduce an alternative
therapy are both equally deleterious to optimal manage-
ment strategy and hence prejudicial to outcome. Thus, a
critical limitation of outcome enhancement is reflective
of three issues: 1) a paucity of specific targeted therapeutic
agents and the inability to preemptively identify the* Correspondence: imodlin@optonline.net
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unless otherwise stated.molecular target; 2) imagery that is relatively insensitive
due both to low discriminant index and the indolent na-
ture of the disease and thirdly, a dearth of sensitive NET-
specific biomarkers to identify alteration in disease status.
In this respect, the currently used blood index, chromo-
granin A (CgA) is relatively non-specific, has low sensitiv-
ity, diverse assay interpretations of normality and defines a
secretory product as opposed to specific indices of neuro-
endocrine tumor cell biology [3].
We have developed and published a blood based mul-
tigene (n = 51) transcript neuroendocrine specific index
to identify NET disease status [4]. The sensitivity and
specificity provide substantial information additive to
current imaging techniques and plasma CgA levels in es-
tablishing alterations in disease status. This case illus-
trates the advantages inherent in utilizing multiple
tumor-specific gene markers to identify early and spe-
cific changes in disease progression not detectable by
standard imagery and biomarker analysis.
Case presentation
A fifty-five year old male with a history of hypertension,
hyperlipidemia and renal calculi presented in December
2001 with flushing and mildly elevated 24 hr urinary
5-hydroxyindole acetic acid (U-5HIAA) (“carcinoid
syndrome”). A small bowel neuroendocrine tumorLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Distinctive appearance at 11C-HTP and 68Ga-SST PET/
CT of the liver (A and D) and bone metastases (B and E); no
other lesions were detected at control PET scan performed
with 68Ga-SST (C).
Figure 2 Time line correlating plasma CgA measurements
(DAKO ELISA, U/L) and the NET Index (%) (both y-axis) with the
imaging and interventions (x-axis).
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metastases (NELMs) (2.8, 6.5 cm) was identified by
OctreoScan® and MRI (CT identified one abnormality). A
distal ileal resection with mesenteric lymphadenectomy,
appendectomy and right lobe hepatic resection with
cholecystectomy, was undertaken.
Histology (2001) indicated a Grade 2 NET, staging: T3,
N2 (4/4), M1, G2, V1, R0. Ki-67 was not undertaken.
His postoperative course was complicated by a right
sub-diaphragmatic abscess, Staphylococcus aureus sepsis
and was treated with antibiotics and percutaneous drain-
age. Annual follow-up, using CT, MRI, OctreoScan® and
PET/CT, was instituted.
Initial progression free survival was three years. There-
after, 11C-5HTP-PET/CT detected local mesenteric re-
currence and re-resection of mesenteric lymph nodes
was undertaken (March 2005, September 2006). Plasma
chromogranin A (CgA) and U-5HIAAs were normal. A
repeat 11C-5HTP-PET/CT (July 2007) identified no ab-
normal tracer accumulation, CgA was slightly elevated
(23U/ml, upper limit of normal = 19U/ml: DAKO ELISA
Kit [K0025] [5]) but U-5HIAA was normal. In April
2008, octreotide (20 mg) was empirically initiated (x1)
but severe nausea and diarrhea precluded further ther-
apy. CgA and U-5HIAA remained normal (June-July
2008). In October 2008, 11C-5HTP-PET-CT identified a
solitary liver metastasis at the resection margin (right
lobe); both CgA and U-5HIAA were normal, circulating
51 marker gene NET Index [4] were elevated. The me-
tastasis was successfully percutaneously cryoablated
(December 2008).
In April 2009, 11C-5HTP-PET/CT demonstrated five
small (<1 cm) NELMs and a rib lesion (Figure 1A-B–yellow
arrows). CgA was elevated (30U/ml) as was the NET Index
(Figure 2–time line correlating plasma CgA with NET
Index and imaging/interventions). Retreatment with
octreotide (20 mg/monthly) was initiated. After 8 months,
lesions were no longer visible (PET/CT December 2009).
No new lesions were evident on PET/CTs, MRIs and col-
onoscopy. In April 2011, CgA was normal. By June 2011,
serotonin was slightly raised (402, ULN = 400U/L). PET/
CT in June identified no abnormalities. The NET index
was abnormal during this period.
A cardiac ECHO (January 2012) identified borderline
LVH, and normal appearing tricuspid valves with trace
insufficiency. In February 2013, 68Ga-DOTATOC-PET/
CT identified hepatic recurrence (Figure 1C–extent of
disease) in Segment IV, periphery of IV-V, and two le-
sions in Segment III (Figure 1D–yellow arrow). Right XII
rib positivity was again noted (Figure 1E–yellow arrow).
CgA levels were normal but the NET Index remained el-
evated. The patient currently exhibits stable residual
NELM disease. A key management concern is the identi-
fication of progressive disease.Discussion
The detection of disease progression remains a key issue
in the management of well-differentiated small bowel
NETs. In most centers, plasma CgA is used in conjunction
with a variety of imaging. Although widely used, CgA ex-
hibits significant limitations in terms of sensitivity and
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(15-47%) of NETs [3]. Imaging, both functional and topo-
graphical, is relatively insensitive in detecting alterations
in indolent disease [6] and histopathological analysis of
resected specimens indicates that imagery fails to detect
~50% of lesions [7]. Although the introduction of 68Ga-
DOTA-PET and 64Cu-DOTATATE has amplified the abil-
ity to detect lesions, the former is not generally available
and the latter is a research technique [8]. Strategies for
early detection of disease recurrence or progression that
inform timely treatment initiation are therefore subopti-
mal [9,10].
Imaging and biomarkers
Imaging (CT, MRI, OctreoScan®, 68Ga-DOTA-PET/CT)
are considered preeminent modalities to assess disease
stability and progression of NELMs [1]. There is, however,
substantial variability in efficacy. The specificity for CT is
as low as 22%, while both MRI and CT are negative in up
to 50% of lesions [11]. The sensitivity (69-86%) of 111In-
octreotide scintigraphy is lower than 68Ga-DOTA-PET/
CT (68Ga-DOTATOC, −DOTANOC or -DOTATATE)
[12] which exhibits the highest sensitivity and specificity
for NELM (82–100%; 67–100%) and extra-hepatic metas-
tasis (85–96%; 67–90%) detection. In addition, 68Ga-
DOTA-PET/CT detects lesions not identified by CT and/
or MRI in up to 67% of patients [6,13]. 18F-DOPA-PET
and 11C-5-HTP-PET have some utility in functionally ac-
tive NETs but are not publically available. Furthermore,
they are not theranostics and do not possess a therapeutic
counterpart [14]. More recently, use of 64Cu-DOTATATE
may surpass 111In and, theoretically, 68Ga in imaging sen-
sitivity [8]. Irrespective, it is apparent that >50% of all
NELMs will be under-staged (pathological analysis of sur-
gical specimens) [7].
The use of individual peptides as biomarkers to iden-
tify early alteration in disease status has proved of lim-
ited value (e.g., pancreatic polypeptide) or amines (e.g.,
serotonin) although gastrin, glucagon and insulin are
useful in specific NETs [15,16]. Overall, the most widely
used is CgA which broadly correlates with hepatic tumor
burden and survival [17]. Elevations may be associated
with tumor progression and in one report increased in
100% with progressive NELMs (disease relapse) [18]. In
a retrospective analysis, a reduction of ≥80% was pre-
dictive of complete resolution of symptoms and disease
stabilization [19]. In a separate study, CgA elevation was
associated with residual disease [20]. Problems with CgA
include no relationship to tumor grade (which is prog-
nostic for survival), concerns regarding sensitivity and
specificity, and the absence of any universally accepted
assay methodology [3,21]. The alternative, U5-HIAA,
has limitations in terms of specificity and sensitivity
[22,23]. Nevertheless, a reduction of U5-HIAA levels ≥80%(or normalization) is reported as predictive of symptom-
atic relief, but not of disease progression [19].
Given the limitations of single agent biomarker ana-
lysis (CgA), we developed a multi-transcript (n = 51
gene) molecular signature for PCR-blood analysis based
on specific neuroendocrine tumor cell transcripts identi-
fied by mathematical analysis of 15 NET tissue microar-
rays [4]. Gene co-expression network inferences and
functional enrichment analyses of tumor tissue and per-
ipheral blood NET transcriptomes (n = 22) identified 51
candidate genes. A test set of NETs (n = 130) was used
to measure gene expression by hydrolysis-based qPCR
and a tumor detection classifier was built using four
learning algorithms (Support Vector Machine, Linear
Discrimination Analysis, K-Nearest Neighbor and Naïve
Bayes). This classification algorithm was validated in two
independent NET sets (n = 115, n = 120) and exhibited a
high sensitivity (85–98%), and specificity (93–97%) for
NET detection including gastric, pancreatic and intes-
tinal NETs. This significantly outperformed (ROC AUC:
0.95-0.98 vs. AUC: 0.64, p < 0.0001) CgA measurements
[4]. Recently, this approach has been validated in a pro-
spectively collected patient series [24]. To quantify data
we developed a classification algorithm - NET Index (0 =
no disease,100 = active disease) [25]. The index identifies
progressive disease with a sensitivity and specificity of 91%
respectively [25]. In this case study we evaluated the utility
of blood CgA levels (ELISA) and the peripheral blood
hydrolysis-based qPCR of the 51 marker genes (NET
Index) derived from in using imaging as a baseline
comparator.
1) CgA levels
The first documented CgA measurement was made five
years after initial diagnosis and was normal despite evi-
dence of a mesenteric mass. Two years later, CgA levels
remained normal despite a 0.5 cm NELM. CgA remained
normal following cryoablation but became elevated after
2 months when bone and liver metastases were noted at
PET-CT. Thereafter CgA levels normalized and remained
within normal limits. Elevated CgA was only briefly de-
tectable following cryotherapy when metastases were evi-
dent on imaging, but was normal when the hepatic
metastatic burden was five lesions (>1 cm).
2) NET index
Circulating tumor transcripts were measured from the
same samples (collected from 2008) as CgA. PCR ana-
lysis and establishment of the NET index product can be
made within 8 hours of blood collection. The NET
Index was elevated (95–100) from initial visit (December
2008) when residual tumor was evident by imaging (CgA
was normal). After cryotherapy, CgA levels decreased
(30%) but blood transcripts remained elevated and were
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itional metastases (April 2009). The NET Index remained
high despite initiation of octreotide (20 mg, January 2009)
and only trended down in May and November 2010 when
PET-CT identified no disease to be present. Lower levels
appeared to correlate with efficacy of octreotide-therapy.
Transcript levels remained low until January 2011 when
progressive increases in the NET Index were noted. The
highest NET Index (November 2011) was also concordant
with the elevated serotonin; at this time, CgA levels
were normal. The NET Index elevations preceded the
68Ga-PET CT identification of five NELMs (February
2013). It should be noted that both a functional PET/CT
with 11C-5-HTP (July 2011) and an MRI (January 2012)
failed to detect disease at these time points. It is likely that
the five lesions noted in (2013) were too small to be de-
tected by PET/CT and MRI (July 2011, January 2012 scans).
Conclusions
This case report describes the limitations and discrepan-
cies in assessing NET disease status by imaging and
CgA. It provides preliminary information revealing the
utility of a multi-transcript gene neuroendocrine tumor-
selective panel.
Although CgA became transiently elevated following
cryotherapy (evidence of NET destruction or surgical
stress-related events), it has significant limitations for le-
sions ≤0.5 cm and can be normal despite the presence of
somatostatin-avid lesions of ~1 cm [26]. Further difficul-
ties are false positive elevations noted with concomitant
proton pump inhibitor use and hypertension, cardiac
disease and other endocrine pathology [3]. U-5HIAA
can be falsely elevated by tryptophan-enriched foods and
drugs but is elevated in ~88% of individuals with carcin-
oid syndrome (overall 10-15% of NETs) [22]. Twenty-
four hour collection, storage and transportation render
it inconvenient. The NET Index, in contrast, is not ele-
vated by long-term PPI usage [4], cardiac disease or
hypertension and was positive in all situations where im-
aging identified lesions (irrespective of size). Overall, the
NET index was more sensitive than CgA in identifying
neuroendocrine lesions and elevation was evident prior
to image-based tumor confirmation in this patient.
Measurement of a multi-transcript gene panel developed
for gastroenteropancreatic NETs in blood provides a
more sensitive and specific alternative to CgA in the
diagnosis and management of NETs and with confirm-
ation of these results in additional cases, demonstrate
utility as an index of therapeutic efficacy.
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